Photo by bermixstudio from unsplash
ABSTRACT A 71-year-old man was referred for 177Lu-PSMA therapy. He had metastatic castration-resistant prostate cancer, progressive on several treatment lines, with current PSA 260 μg/L and deteriorating condition. CT showed… Click to show full abstract
ABSTRACT A 71-year-old man was referred for 177Lu-PSMA therapy. He had metastatic castration-resistant prostate cancer, progressive on several treatment lines, with current PSA 260 μg/L and deteriorating condition. CT showed ascites with omental and peritoneal metastases, all positive on PSMA PET/CT. He was treated with 4 cycles of 7.4 GBq (0.2 Ci) 177Lu-PSMA-I&T. Posttherapy scans showed good targeting of all metastases. After 4 cycles, PSA had dropped to 44 μ/L. Four months after the fourth cycle, the patients' general condition had significantly improved, and PSA had decreased to 7.0 μg/L.
Journal Title: Clinical nuclear medicine
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!